Thalidomide treatment of resistant or relapsed multiple myeloma patients

Haematologica

Volumn 86, Issue 4, 2001, Pages 404-408

  Hus, M ^a   Dmoszynska, A ^a   Soroka Wojtaszko, M ^a   Jawniak, D ^a   Legiec, W ^a   Ciepnuch, H ^a   Hellmann, A ^a   Wolska Smolen, T ^a   Skotnicki, A ^a   Manko, J ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Multiple myeloma; Refractory; Thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; C REACTIVE PROTEIN; IMMUNOGLOBULIN; LACTATE DEHYDROGENASE; PARAPROTEIN; THALIDOMIDE;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; BRADYCARDIA; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROPHORESIS; FEMALE; FEVER; FOLLOW UP; HUMAN; KIDNEY FUNCTION TEST; LEUKOPENIA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; NEUROTOXICITY; PLASMA CELL; RASH; TREATMENT OUTCOME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; THALIDOMIDE; TREATMENT OUTCOME;

EID: 0035007047     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Angiogenesis in newly diagnosed multiple myeloma: Poor prognosis with increased microvessel density in bone marrow biopsies
2. Antitumor activity of thalidomide in refractory multiple myeloma
3. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies
4. The rationale and future potential of angiogenesis inhibitors in neoplasia
5. Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44
6. Bone morrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
7. Immunophenotype changes in multiple myeloma patients during thalidomide treatment
8. Thalidomide once again. Novel clinical application
9. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
10. Initiation and maintenance of multiple myeloma
11. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
12. S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide
13. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
14. Single course DT PACE antiangiochemotherapy effects CR in plasma cell and fulminate multiple myeloma
15. Total therapy with tandem transplants for newly diagnosed multiple myeloma
16. Therapy with thalidomide in refractory multiple myeloma patients: The revival of an old drug
17. Efficacy of low dose thalidomide in multiple myeloma
18. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma
19. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal human progenitors
20. Thalidomide for the treatment of multiple myeloma relapsing after autologous peripheral blood progenitor cell transplant
21. Effective thalidomide therapy of a patient primarily resistent to chemotherapy for multiple myeloma